media – Page 7 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Expopharm-Mexico

Organiser：Mexican Pharmaceutical Association Time：April 17th – 19th, 2025 Address：Conscripto 311, Colonia Lomas de Sotelo, Delegación Miguel Hidalgo, 11200, México D.F. Exhibition hall：Centro Banamex Product range: API Equipment: Reaction equipment, drying equipment, crystallization equipment, centrifuges, extraction equipment, heat exchangers, storage equipment, filtration equipment, evaporation equipment, distillation equipment, screening machinery, sterilization equipment, filter press equipment, homogenizers, etc. Pharmaceutical Preparation Equipment: Pill machinery, ointment machinery, eyedrop machinery, tablet machinery, tincture and syrup machinery, granule machinery, soft capsule machinery, aqueous injection machinery, hard capsule machinery, suppository machinery, oral liquid machinery, medicinal film machinery, aerosol machinery, antibiotic powder machinery, aqueous injection machinery, infusion machinery, tablet pressing machines, coating machines, medicinal filling machines, air jet mills, pharmaceutical grinding machines, mechanical pharmaceutical crushing machines, ultra-fine grinding machines, granulating machines, mixing equipment, bottle conveyors, bottle aligning machines, oscillating capping devices, feeding devices, etc. Pharmaceutical Packaging Machinery: Weighing equipment, bag packaging machines, pillow packaging machines, blister packaging machines, ...
- Source: drugdu
- 81
- December 17, 2024
2024 SABCS | Zhengda Tianqing Announces the Latest Data of Arrotinib Treatment for breast cancer

The 47th San Antonio breast cancer Symposium (SABCS) in 2024, held in the United States from December 10 to 13, is one of the largest and most prestigious academic events in the field of breast cancer research. At this conference, Zhengda Tianqing focused on HR+/HER2- and triple negative breast cancer, and released a number of clinical research data based on arotinib. The objective response rate (ORR) of the triple negative breast cancer study, which is called “the most toxic breast cancer”, is as high as 75.0%; The disease control rate (DCR) in the treatment of breast cancer patients with CDK4/6 inhibitor resistant HR+breast cancer was 94.9%. Efficacy and safety of the first-line treatment of advanced triple negative breast cancer with arotinib combined with paianzulimab and albumin bound paclitaxel: a prospective, phase II clinical study Forty three patients with inoperable locally advanced or recurrent/metastatic triple negative breast cancer (TNBC) with an ...
- Source: drugdu
- 52
- December 17, 2024
Maiwei Biotechnology and Chongqing High tech Zone Management Committee plan to invest 2 billion yuan in the construction of the “Bone Health Innovative Drug Project”

On December 16th, Shanghai Stock Exchange China Securities Network (Reporter Wang Mopujia) announced that Maiwei Biotechnology has signed a “Maiwei Biotechnology Bone Health Innovation Drug Project Contract” with the Chongqing High tech Industrial Development Zone Management Committee (referred to as “Chongqing High tech Zone Management Committee”) and the Chongqing Zhongxin Pharmaceutical Big Health Private Equity Investment Fund Partnership Enterprise (Limited Partnership) (referred to as “Big Health Fund”). Maiwei Biotechnology (Chongqing) Co., Ltd. (referred to as “Maiwei Chongqing”), a wholly-owned subsidiary of the company, will jointly invest in and construct the “Maiwei Biotechnology Bone Health Innovation Drug Project” as the project operating entity. It is reported that the total planned investment for the above-mentioned project is 2 billion yuan, of which Maiwei Biotechnology has a total investment of no less than 1.6 billion yuan (1.008 billion yuan in this round of investment), which will be contributed in the form of ...
- Source: drugdu
- 49
- December 17, 2024
Anjisheng Biotechnology completes $120 million Series C financing

On December 11th, Angitia announced the completion of a $120 million Series C funding round led by Bain Capital Life Sciences. The participants in this round of investment include new investor Janus Henderson and existing shareholders Aobo Capital, Sanzheng Health Investment, Yonghua Investment, Junlian Capital, and Lichen Investment. According to the press release, the proceeds from Series C financing will be used to support Anjisheng’s innovative drug pipeline, dedicated to developing differentiated and innovative treatment plans for critical bone, joint, and muscle diseases. Anjisheng Biotechnology is an innovative drug research and development company specializing in the field of severe diseases of bones, joints, and muscles. Currently, three biopolymer candidate drugs are in the clinical research stage, aimed at treating osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Among them, the company is advancing the global clinical development of AGA2118 and AGA2115 for the treatment of osteoporosis and osteogenesis imperfecta (OI). These ...
- Source: drugdu
- 59
- December 17, 2024
Interventional valve surgery robot completes Series C financing

According to the Medicine Intelligence Data Investment Pattern Database, Capstan Medical, a robotics company specializing in interventional valve surgery, recently announced the successful completion of its Series C financing, raising a total of $110 million (contract amount of RMB 800 million). This round of financing is led by Eclipse, with existing investors such as Yu Galaxy and Intuitive Ventures participating, while introducing new investor Gideon Strategic Partners. It is reported that the funds raised in this round are intended to be used to bring its robot assisted minimally invasive solution to the market to solve heart valve diseases. In addition, according to the Pharmaceutical Intelligence Data Investment Pattern Database, Capstan Medical has completed two rounds of financing, with the last round being the B-round financing completed on August 9, 2023, raising a total of 31.4 million US dollars (contract 230 million RMB). Valve disease (VHD) is a structural heart disease ...
- Source: drugdu
- 56
- December 17, 2024
Liu Yongjun resigns from CSPC

Liu Yongjun resigned at the speed of light. On December 9, according to media reports, Liu Yongjun had resigned from CSPC, just three months after the official announcement of joining. On September 9 this year, CSPC issued an announcement on the Hong Kong Stock Exchange, announcing the appointment of Liu Yongjun as the group’s executive president and global R&D president, responsible for the group’s R&D, pipeline strategy and international business development. It may be rare in the industry for a senior executive in this position to resign within three months. Combined with a series of personnel, capital and innovation strategy changes from CSPC to its innovative pharmaceutical subsidiary in the past three months, it can be seen that CSPC may be facing certain challenges in innovation, R&D, and internationalization. This also highlights the fact that the transformation of most traditional pharmaceutical companies may end in failure. After all, innovation cannot ...
- Source: drugdu
- 46
- December 17, 2024
It is not surprising that aspirin costs 3 cents a piece

In the tenth batch of national procurement, aspirin has become the focus. The core reason is that in this batch of centralized procurement, the price of enteric-coated aspirin tablets is as low as 3 cents a piece. The market is worried that excessive pursuit of low prices in centralized procurement may hurt companies, after all, this will affect profits; at the same time, it may also cause drug quality problems, and some media even lead the rhythm: “Do you dare to take drugs that cost 3 cents a piece in centralized procurement?” The market’s concerns are understandable, but most of the emotions may be redundant. First of all, due to the simple synthesis process and cheap raw materials, the cost of aspirin itself is not high. In Europe and the United States, the unit price of aspirin is basically in “cents”. The article “What is the level of 3 cents ...
- Source: drugdu
- 68
- December 17, 2024
Want to win again with CAR-T

Gilead has been in Mercury retrograde in the past two years. Apart from long-acting HIV therapy, there is almost no good news, especially in the anti-tumor field where Gilead continues to increase its layout. It can even be said that the harder it tries, the more disappointed it is. Not only has it suffered a lot in the layout of TIGIT, but since this year, Trodelvy has failed in clinical trials, resulting in a high probability that the $21 billion acquisition of Immunomedics will be difficult to recover, and the $4.9 billion investment in the CD47 field is even more lost. Of course, even after paying a huge tuition fee, Gilead is still fighting for growth, active in the field of tumor BD, betting on new products and new technologies. At present, compared with these earlier bets, Gilead obviously hopes to win again with CAR-T. Recently, the clinical data of ...
- Source: drugdu
- 53
- December 17, 2024
The highest unit price is 176,000 yuan, dismantling the first cell storage stock

Cell storage has never been a new topic. In the promotion of cell storage, these precious biological resources, from stem cells to immune cells, can be stored in case of emergency through freezing, and play a key role in treating diseases, delaying aging and even regenerative medicine. Simply put, storing your own cells is an investment in future health, although this is expensive. “The most expensive unit price is 176,000 yuan, and it is stored for 20 years,” Shanghai Cell Therapy Group, which applied for an IPO on the Hong Kong stock market, revealed to us the tip of the iceberg of the cell storage business. Relying on the cell storage business, Shanghai Cell Therapy Group earns 600 million yuan a year and supports the company’s IPO. So, what is the clinical value of cell storage? What kind of business is this? The reason why it is called “the first ...
- Source: drugdu
- 38
- December 17, 2024
Xinghao Pharmaceutical’s Naloxone Hydrochloride Injection Expected to Win Bid in the Tenth National Centralized Procurement

On December 12, Xinghao Pharmaceutical announced that its subsidiary, Guangdong Xinghao Pharmaceutical Co., Ltd., participated in the bidding process organized by the Joint Procurement Office for the tenth batch of national centralized drug procurement. The company’s product, Naloxone Hydrochloride Injection, is expected to win the bid in this centralized procurement, with an intended bid price of 1.37 yuan per vial. It is reported that Naloxone Hydrochloride Injection is an opioid receptor antagonist used to counteract respiratory depression caused by opioid drugs in narcotic anesthesia and to promote patient awakening, as well as to rescue individuals from acute ethanol poisoning. Xinghao Pharmaceutical stated that if the company subsequently signs a procurement contract and implements it, this will further expand the sales of related products, increase market share, enhance the company’s brand influence, and have a positive impact on the company’s future operating performance. https://finance.eastmoney.com/a/202412133267927671.html
- Source: drugdu
- 45
- December 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.